Multicenter Open-label Study to Evaluate Efficacy of Gadobutrol-enhanced Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Significant Coronary Artery Disease (CAD) in Subjects With Known or Suspected CAD by a Blinded Image Analysis

Trial Profile

Multicenter Open-label Study to Evaluate Efficacy of Gadobutrol-enhanced Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Significant Coronary Artery Disease (CAD) in Subjects With Known or Suspected CAD by a Blinded Image Analysis

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Gadobutrol (Primary)
  • Indications Coronary artery disease
  • Focus Diagnostic use
  • Acronyms GadaCAD 2
  • Sponsors Bayer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 17 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top